Press Releases

INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021

Posted on October 27, 2021

INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa

Posted on October 26, 2021

INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives

Posted on October 21, 2021

INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800

Posted on October 12, 2021

INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization

Posted on October 11, 2021

INOVIO to Present Three Posters at IDWeek 2021

Posted on September 29, 2021

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

Posted on September 22, 2021

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800

Posted on August 26, 2021

INOVIO Reports Second Quarter 2021 Financial Results

Posted on August 9, 2021

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO’s COVID-19 DNA Vaccine Candidate

Posted on August 9, 2021

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.